ScriptSwitch is US bound

Emmet Keating (Catalyst), Mike Washburn (MD ScriptSwitch), Mark Lovett (COO ScriptSwitch), Jamie Hope (Catalyst)

Catalyst has acted for the shareholders of ScriptSwitch, which included ISIS Equity Partners, Advantage Growth Fund and the management team, on its sale to UnitedHealth UK, part of US corporate UnitedHealth Group Inc.

ScriptSwitch is the leading provider of software designed to support GPs with patient safety information, drug switch recommendations and dosage optimisation information at the point of prescribing. ISIS originally supported the £10m secondary buy-out of ScriptSwitch in May 2007, since when the company has grown rapidly, increasing the number of patients with access to its services by more than 250%. Given the rapid growth of ScriptSwitch, there was significant interest in the company from both the UK and overseas.

We helped the shareholders prepare the business for sale, and then used our extensive international contacts to source a strategic buyer from the US. The deal completed within 4 weeks of agreeing exclusivity. For more on how we worked on this deal and made the difference see here

This sale is the third Healthcare IT deal advised by Catalyst in 2009, following the sales of CHKS to Capita plc and Iasist to UBM plc, and we continue to be active in the healthcare sector, in particular primary care. To read more about our Healthcare research, or to subscribe to our sector opinions see here